Shanghai Haohai Biological Technology Co Ltd 2024 SR
The report highlights the company's focus on ophthalmology, medical aesthetics, orthopedics, and surgery. In 2024, five new products were launched, and significant progress was made in clinical trials for six others. The company achieved Grade A in Wind and Sino-Securities ESG ratings. Environmental performance remained stable, with ISO 14001 and ISO 45001 certifications obtained. Social contributions included RMB 831,700 in public welfare and charitable investments, with zero workplace fatalities.
Company: Shanghai Haohai Biological Technology Co Ltd
Sector: Manufacturing
Country: China
Year: 2024
Type: SR
Pages: 70
Back to company
Shanghai Haohai Biological Technology Co Ltd
ESG Report
The report highlights the company's focus on ophthalmology, medical aesthetics, orthopedics, and surgery. In 2024, five new products were launched, and significant progress was made in clinical trials for six others. The company achieved Grade A in Wind and Sino-Securities ESG ratings. Environmental performance remained stable, with ISO 14001 and ISO 45001 certifications obtained. Social contributions included RMB 831,700 in public welfare and charitable investments, with zero workplace fatalities.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Published
Apr 25, 2025
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Total Waste
Workplace Fatalities
Employees